美洛昔康、昔布类药物及 older, non-specific non-steroidal anti-inflammatory drugs使用者的引导性偏倚与胃肠道出血发生率（注：这里“older, non-specific non-steroidal anti-inflammatory drugs”表述不太准确规范，可能是指传统非特异性非甾体抗炎药之类的意思，但按要求直接翻译）

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

作者信息

MacDonald T M, Morant S V, Goldstein J L, Burke T A, Pettitt D

机构信息

Medicines Monitoring Unit, Department of Clinical Pharmacology and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

出版信息

Gut. 2003 Sep;52(9):1265-70. doi: 10.1136/gut.52.9.1265.

DOI:10.1136/gut.52.9.1265

PMID:12912856

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1773795/

Abstract

BACKGROUND

Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.

AIMS

To estimate whether meloxicam and the coxibs, rofecoxib and celecoxib, have been channelled towards high risk patients, and to estimate the risk of hospitalisation for gastrointestinal haemorrhage associated with the use of these drugs, allowing for the effects of channelling.

PATIENTS

Using the UK General Practice Research Database, this study included 7.1 thousand patient years (tpy) exposure to meloxicam, 1.6 tpy exposure to coxibs, and 628 tpy exposure to older non-specific NSAIDs.

METHODS

Cohort study of patients who received a prescription for an NSAID between June 1987 and January 2001. Exposure to newer NSAIDs (meloxicam, rofecoxib, celecoxib) and to older non-specific NSAIDs was identified. Channelling was assessed on factors including: demographic variables; diagnosis of arthritis; history of NSAID use or gastrointestinal events, including gastrointestinal haemorrhage; and use of ulcer healing drugs.

RESULTS

Most risk factors for gastrointestinal haemorrhage were more prevalent among patients prescribed the newer NSAIDs. Adjusting for these risk factors reduced the relative risks of gastrointestinal haemorrhage on meloxicam and coxibs versus older non-specific NSAIDs to 0.84 (95% confidence interval 0.60, 1.17) and 0.36 (0.14, 0.97), respectively.

CONCLUSIONS

Channelling towards high risk gastrointestinal patients occurred in the prescribing of newer NSAIDs. After attempting to correct for channelling bias, coxib exposure, but not meloxicam exposure, was associated with a significantly lower risk of gastrointestinal haemorrhage than older non-specific NSAID exposure.

摘要

背景

尽管临床试验结果表明，美洛昔康的胃肠道毒性低于大多数其他非甾体抗炎药（NSAIDs），但在实际应用中，它已与大量关于胃肠道并发症的黄卡报告相关联。

目的

评估美洛昔康、昔布类药物（罗非昔布和塞来昔布）是否被用于高危患者，并评估使用这些药物导致胃肠道出血住院的风险，同时考虑用药倾向的影响。

患者

利用英国全科医疗研究数据库，本研究纳入了7100患者年（tpy）的美洛昔康暴露、1600 tpy的昔布类药物暴露以及628 tpy的 older non-specific NSAIDs暴露。

方法

对1987年6月至2001年1月期间接受NSAIDs处方的患者进行队列研究。确定了对新型NSAIDs（美洛昔康、罗非昔布、塞来昔布）和 older non-specific NSAIDs的暴露情况。根据以下因素评估用药倾向：人口统计学变量；关节炎诊断；NSAIDs使用史或胃肠道事件史，包括胃肠道出血；以及溃疡愈合药物的使用情况。

结果

大多数胃肠道出血的危险因素在开具新型NSAIDs处方的患者中更为普遍。对这些危险因素进行调整后，美洛昔康和昔布类药物相对于 older non-specific NSAIDs导致胃肠道出血的相对风险分别降至0.84（95%置信区间0.60，1.17）和0.36（0.14，0.97）。

结论

在新型NSAIDs的处方中存在将药物用于高危胃肠道患者的用药倾向。在试图纠正用药倾向偏差后，与 older non-specific NSAIDs暴露相比，昔布类药物暴露而非美洛昔康暴露与显著更低的胃肠道出血风险相关。

相似文献

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

Gut. 2003 Sep;52(9):1265-70. doi: 10.1136/gut.52.9.1265.

Application of a propensity score to adjust for channelling bias with NSAIDs.

Pharmacoepidemiol Drug Saf. 2004 Jun;13(6):345-53. doi: 10.1002/pds.946.

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.

Rheumatology (Oxford). 2003 Nov;42(11):1332-41. doi: 10.1093/rheumatology/keg376. Epub 2003 Jun 16.

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.

Rheumatology (Oxford). 2003 May;42(5):622-31. doi: 10.1093/rheumatology/keg141.

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

BMJ. 2002 Sep 21;325(7365):624. doi: 10.1136/bmj.325.7365.624.

Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.

Eur Ann Allergy Clin Immunol. 2004 Jun;36(6):215-8.

Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.

Aliment Pharmacol Ther. 2003 Feb;17(3):321-32. doi: 10.1046/j.1365-2036.2003.01454.x.

Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.

Drug Saf. 2006;29(3):261-72. doi: 10.2165/00002018-200629030-00009.

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.

Rheumatology (Oxford). 2003 Nov;42(11):1354-64. doi: 10.1093/rheumatology/keg401. Epub 2003 Jul 16.

Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.

J Asthma. 2004 Feb;41(1):67-75. doi: 10.1081/jas-120026063.

引用本文的文献

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies.

Neurotherapeutics. 2023 Mar;20(2):375-388. doi: 10.1007/s13311-023-01344-w. Epub 2023 Mar 2.

Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.

J Vet Pharmacol Ther. 2022 Jul;45(4):325-351. doi: 10.1111/jvp.13052. Epub 2022 Apr 22.

Ibuprofen and Paracetamol: Acceptably Safe for All?

Drug Saf. 2018 Nov;41(11):999-1001. doi: 10.1007/s40264-018-0717-4.

Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study.

Clin Epidemiol. 2017 Jan 18;9:19-30. doi: 10.2147/CLEP.S124054. eCollection 2017.

Frequency of nonsteroidal anti-inflammatory drug-associated ulcers.

Clin J Gastroenterol. 2012 Jun;5(3):171-6. doi: 10.1007/s12328-012-0300-y. Epub 2012 Apr 24.

Comparison of preemptive analgesic effects of a single dose of nonopioid analgesics for pain management after ambulatory surgery: A prospective, randomized, single-blind studyin Turkish patients.

Curr Ther Res Clin Exp. 2005 Nov;66(6):541-51. doi: 10.1016/j.curtheres.2005.12.001.

Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).

Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.

High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

Eur J Clin Pharmacol. 2013 Mar;69(3):549-57. doi: 10.1007/s00228-012-1334-2. Epub 2012 Jul 5.

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.

PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.

Ameliorative effect of ocimum sanctum on meloxicam induced toxicity in wistar rats.

Toxicol Int. 2011 Jul;18(2):130-6. doi: 10.4103/0971-6580.84265.

本文引用的文献

Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin.

Pharmacoepidemiol Drug Saf. 2000 Mar;9(2):113-7. doi: 10.1002/(SICI)1099-1557(200003/04)9:2<113::AID-PDS478>3.0.CO;2-2.

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

BMJ. 2002 Sep 21;325(7365):624. doi: 10.1136/bmj.325.7365.624.

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

BMJ. 2002 Sep 21;325(7365):619. doi: 10.1136/bmj.325.7365.619.

Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.

Clin Exp Rheumatol. 2002 Jan-Feb;20(1):35-43.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103.

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Arch Intern Med. 2000 Oct 23;160(19):2998-3003. doi: 10.1001/archinte.160.19.2998.

Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.

Arch Intern Med. 2000 Oct 23;160(19):2947-54. doi: 10.1001/archinte.160.19.2947.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

J Rheumatol. 2000 Aug;27(8):1876-83.

Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.

Am J Gastroenterol. 2000 Jul;95(7):1681-90. doi: 10.1111/j.1572-0241.2000.02194.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

美洛昔康、昔布类药物及 older, non-specific non-steroidal anti-inflammatory drugs使用者的引导性偏倚与胃肠道出血发生率（注：这里“older, non-specific non-steroidal anti-inflammatory drugs”表述不太准确规范，可能是指传统非特异性非甾体抗炎药之类的意思，但按要求直接翻译）

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

作者信息

MacDonald T M, Morant S V, Goldstein J L, Burke T A, Pettitt D

机构信息

Medicines Monitoring Unit, Department of Clinical Pharmacology and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

出版信息

Gut. 2003 Sep;52(9):1265-70. doi: 10.1136/gut.52.9.1265.

DOI:10.1136/gut.52.9.1265

PMID:12912856

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1773795/

Abstract

BACKGROUND

AIMS

PATIENTS

METHODS

RESULTS

CONCLUSIONS

摘要

背景

目的

患者

利用英国全科医疗研究数据库，本研究纳入了7100患者年（tpy）的美洛昔康暴露、1600 tpy的昔布类药物暴露以及628 tpy的 older non-specific NSAIDs暴露。

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

作者信息

机构信息

出版信息

BACKGROUND

AIMS

PATIENTS

METHODS

RESULTS

CONCLUSIONS

背景

目的

患者

方法

结果

结论

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

作者信息

机构信息

出版信息

BACKGROUND

AIMS

PATIENTS

METHODS

RESULTS

CONCLUSIONS

背景

目的

患者

方法

结果

结论